You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
E
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Not yet recruiting
  • Chronic Myeloid Leukemia
  • (no location specified)
2022-03-30
Mar 30, 2022
A
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia - 2021
Terminated
Has Results
  • Chronic Phase Chronic Myeloid Leukemia
  • Ponatinib 30 mg QD
  • +2 more
  • Bruxelles, Belgium
    Cliniques Universitaire Saint-Luc (Site 058)
2021-10-28
Oct 28, 2021
S
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Recruiting
  • Dasatinib
  • +2 more
  • Shenzhen, Guangdong, China
    Xin Du
2022-03-15
Mar 15, 2022
A
TIGIT in Patients With Chronic Myeloid Leukemia
Not yet recruiting
  • Chronic Myeloid Leukemia
  • flow cytometry test
  • (no location specified)
2021-03-25
Mar 25, 2021
A
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
Not yet recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • +3 more
  • Augusta, Georgia
    Georgia Cancer Center at Augusta University
2021-11-23
Nov 23, 2021
H
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
Not yet recruiting
  • Chronic Myeloid Leukemia
  • Cairo, Egypt
  • +1 more
2022-03-16
Mar 16, 2022
T
A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia
Recruiting
  • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Chronic Phase Chronic Myelogenous Leukemia
  • Text Message-Based Navigation Intervention
  • Survey Administration
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
2022-04-07
Apr 7, 2022
U
Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose
Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
    • Jena, Germany
      University Hospital Jena
    2021-08-12
    Aug 12, 2021
    C
    Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia
    Recruiting
    • Chronic Myeloid Leukemia
    • Pharmaceutical intervention
    • Saint-Étienne, France
      CHU de Saint-Etienne
    2022-02-24
    Feb 24, 2022
    W
    Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy - 2021
    Completed
    Has Results
    • Chronic Myeloid Leukemia
    • New York, New York
      Weill Cornell Medical College
    2022-03-24
    Mar 24, 2022
    M
    Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy - 2022
    Completed
    • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +4 more
    • Eltrombopag Olamine
    • Houston, Texas
      M D Anderson Cancer Center
    2022-01-04
    Jan 4, 2022
    M
    ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor
    Recruiting
    • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    • Houston, Texas
      M D Anderson Cancer Center
    2022-02-01
    Feb 1, 2022
    B
    Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
    Recruiting
    • Chronic Myeloid Leukemia
    • +2 more
    • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
    • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
    • Houston, Texas
    • +3 more
    2022-01-25
    Jan 25, 2022
    S
    The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
    Recruiting
    • Chronic Myeloid Leukemia in Chronic Phase
    • Shenzhen, Guangdong, China
      Shenzhen Second People's Hospital
    2022-03-15
    Mar 15, 2022
    H
    Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt - 2020
    Completed
    • Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase
    • Cairo, Egypt
      National Cancer Institute (NCI)
    2021-02-22
    Feb 22, 2021
    P
    Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database - 2022
    Completed
    • Chronic Myeloid Leukaemia
    • Budapest, Hungary
      Pfizer
    2022-03-09
    Mar 9, 2022
    M
    ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
    Recruiting
    • Chronic Phase Chronic Myelogenous Leukemia
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    2021-12-29
    Dec 29, 2021
    G
    Myeloid Mutations Register in R/R CML
    Recruiting
    • Chronic Myeloid Leukaemia Recurrent
    • Chronic Myeloid Leukemia, in Relapse
    • Myeloid mutations measurement
    • Huixquilucan, Estado De México, Mexico
      Grupo Cooperativo de Hemopatías Malignas
    2021-10-04
    Oct 4, 2021
    N
    Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitor in Patients With Chronic Myeloid Leukemia
    Not yet recruiting
    • Tyrosine Kinase Inhibitor
    • +2 more
      • Taipei, Taiwan
        National Taiwan University Hospital
      2022-02-17
      Feb 17, 2022
      M
      Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia - 2021
      Terminated
      • Chronic Myeloid Leukemia, Chronic Phase
      • Eicosapentaenoic Acid
      • Tyrosine kinase inhibitor
      • Hershey, Pennsylvania
        Penn State Cancer Institute
      2021-10-04
      Oct 4, 2021
      A
      FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia
      Recruiting
      • Folate
      • +2 more
        • Nantong, China
          Affliated Hospital of Nantong University
        2021-12-13
        Dec 13, 2021
        N
        Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia
        Recruiting
        • Validity and Safety
          • Guangzhou, Guangdong, China
            NanfangH
          2021-09-02
          Sep 2, 2021
          N
          Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase - 2008
          Terminated
          Has Results
          • Chronic Myeloid Leukemia in Chronic Phase
          • Bruxelles, Belgium
          • +9 more
          2021-07-14
          Jul 14, 2021
          H
          Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
          Active, not recruiting
          • Chronic Myelogenous Leukemia
          • Amman, Jordan
          • +4 more
          2022-01-17
          Jan 17, 2022
          M
          Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
          Recruiting
          • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
          • +2 more
          • Laboratory Biomarker Analysis
          • +2 more
          • Houston, Texas
            M D Anderson Cancer Center
          2022-01-20
          Jan 20, 2022